ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

MANAGEMENT REPORT

Management's Responsibility for Financial Reporting

The accompanying financial statements have been prepared by Mackenzie Financial Corporation, as Manager of Mackenzie Global Dividend Fund (the "Fund"). The Manager is responsible for the integrity, objectivity and reliability of the data presented. This responsibility includes selecting appropriate accounting principles and making judgments and estimates consistent with IFRS Accounting Standards. The Manager is also responsible for the development of internal controls over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors (the "Board") of Mackenzie Financial Corporation is responsible for reviewing and approving the financial statements and overseeing the Manager's performance of its financial reporting responsibilities. The Board meets regularly with the Manager, internal auditors and external auditors to discuss internal controls over the financial reporting process, auditing matters and financial reporting issues.

KPMG LLP is the external auditor of the Fund. It is appointed by the Board. The external auditor has audited the financial statements in accordance with Canadian generally accepted auditing standards to enable it to express to the securityholders its opinion on the financial statements. Its report is set out below.

On behalf of Mackenzie Financial Corporation,

Manager of the Fund

Luke Gould President and Chief Executive Officer

Terry Rountes Chief Financial Officer, Funds

Tag Nas

June 4, 2024

INDEPENDENT AUDITOR'S REPORT

To the Securityholders of Mackenzie Global Dividend Fund (the "Fund")

Opinion

We have audited the financial statements of the Fund, which comprise:

- the statements of financial position as at March 31, 2024 and March 31, 2023
- the statements of comprehensive income for the periods then ended as indicated in note 1
- the statements of changes in financial position for the periods then ended as indicated in note 1
- . the statements of cash flows for the periods then ended as indicated in note 1 and
- notes to the financial statements, including a summary of material accounting policies (Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at March 31, 2024 and March 31, 2023, and its financial performance and cash flows for the periods then ended as indicated in note 1 in accordance with IFRS Accounting Standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Fund in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

INDEPENDENT AUDITOR'S REPORT (cont'd)

Other Information

Management is responsible for the other information. Other information comprises:

- the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions as at the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Fund's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the financial reporting process of the Fund.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Chartered Professional Accountants, Licensed Public Accountants Toronto, Canada

KPMG LLP

June 4, 2024

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF FINANCIAL POSITION

at March 31 (in \$ 000 except per security amounts)

	2024 \$	2023 \$
ASSETS	Ψ	Ψ
Current assets		
Investments at fair value	5,750,541	4,685,514
Cash and cash equivalents	180,833	129,759
Dividends receivable	8,736	5,239
Accounts receivable for investments sold	_	4,311
Accounts receivable for securities issued	10,347	2,761
Due from manager	922	33
Derivative assets	2,423	96
Total assets	5,953,802	4,827,713
LIABILITIES		
Current liabilities		
Accounts payable for investments purchased	13,320	18,437
Accounts payable for securities redeemed	6,907	3,973
Due to manager	1,427	997
Derivative liabilities	944	3,559
Total liabilities	22,598	26,966
Net assets attributable to securityholders	5,931,204	4,800,747

	Net assets attributable to securityholders (note 3)									
	per secu	ırity	per s	eries						
	2024	2023	2024	2023						
Series A	31.93	27.42	1,099,205	946,652						
Series AR	26.16	22.47	133,142	106,772						
Series CL	-	17.15	_	9,025						
Series D	22.60	20.24	22,549	8,258						
Series F	21.40	19.15	1,426,211	938,794						
Series F8	13.69	12.62	19,810	12,189						
Series FB	20.23	17.27	3,866	3,562						
Series FB5	19.88	17.81	38	33						
Series I	19.69	17.69	887	719						
Series IG	11.61	_	1	_						
Series J	28.94	24.80	23	20						
Series 0	22.22	19.83	849,187	816,558						
Series 05	22.77	20.32	2,908	2,477						
Series PW	25.67	21.97	1,617,480	1,267,346						
Series PWFB	17.70	15.10	53,273	40,835						
Series PWFB5	18.97	16.97	270	259						
Series PWR	15.56	13.32	69,761	43,532						
Series PWT5	18.26	16.40	50,236	40,922						
Series PWT6	17.02	15.43	1,656	1,942						
Series PWT8	16.90	15.63	44,591	38,566						
Series PWX	24.61	21.96	25,694	24,741						
Series PWX8	16.88	15.52	2,156	2,010						
Series R	20.14	17.14	207,951	230,169						
Series S	30.91	26.31	22,640	20,037						
Series T5	19.22	17.33	26,988	23,837						
Series T6	16.98	15.46	5,124	5,026						
Series T8	11.57	10.74	16,678	16,671						
Series U	39.34	33.65	716	784						
Series U5	27.64	24.80	56	67						
Series UM	17.07	14.56	73,599	81,800						
Series LB	22.82	19.62	20,259	14,323						
Series LF	17.27	14.73	49,740	34,315						
Series LW	16.41	14.06	84,509	68,506						
			5,931,204	4,800,747						

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF COMPREHENSIVE INCOME

for the periods ended March 31 (in \$ 000 except per security amounts)

	2024 \$	2023 \$
lucama	Þ	Þ
Income	115 055	105.700
Dividends	115,655	105,766
Interest income for distribution purposes	6,983	2,327
Other changes in fair value of investments and other net assets		
	155 001	(15 227)
Net realized gain (loss)	155,901	(15,227)
Net unrealized gain (loss)	676,541	61,232
Securities lending income	327	267
Total income (loss)	955,407	154,365
- (
Expenses (note 6)		
Management fees	68,408	58,523
Management fee rebates	(113)	(116)
Administration fees	8,397	7,151
Interest charges	4	2
Commissions and other portfolio transaction costs	2,445	2,018
Independent Review Committee fees	19	15
<u>Other</u>	27	25
Expenses before amounts absorbed by Manager	79,187	67,618
Expenses absorbed by Manager		
Net expenses	79,187	67,618
Increase (decrease) in net assets attributable to		
securityholders from operations before tax	876,220	86,747
Foreign withholding tax expense (recovery)	14,995	13,202
Foreign income tax expense (recovery)	(119)	(449)
Increase (decrease) in net assets attributable to		
securityholders from operations	861,344	73,994

		to securityholders from operations (note 3)								
	per secu	rity	per sei	ries						
	2024	2023	2024	2023						
Series A	4.51	0.10	155,183	3,562						
Series AR	3.75	0.22	18,427	1,000						
Series CL	1.53	0.88	800	388						
Series D	4.27	0.39	3,022	141						
Series F	3.58	0.48	198,014	21,259						
Series F8	2.33	0.19	2,793	174						
Series FB	3.02	0.39	595	76						
Series FB5	3.09	0.66	6	2						
Series I	3.04	0.44	130	18						
Series IG	1.75	_	114	_						
Series J	4.14	0.18	3	1						
Series 0	3.65	0.40	144,193	17,142						
Series 05	3.82	0.61	475	72						
Series PW	3.77	0.24	223,620	13,482						
Series PWFB	2.77	0.44	7,832	1,028						
Series PWFB5	2.93	(0.07)	47	_						
Series PWR	2.39	0.25	8,884	734						
Series PWT5	2.73	0.12	7,042	297						
Series PWT6	2.37	0.01	252	2						
Series PWT8	2.51	0.24	6,411	540						
Series PWX	4.03	0.27	4,499	327						
Series PWX8	2.83	0.40	364	51						
Series R	3.15	0.72	34,570	9,804						
Series S	4.99	0.74	3,660	553						
Series T5	2.80	(0.02)	3,896	(33)						
Series T6	2.40	(0.02)	747	(6)						
Series T8	1.66	(0.06)	2,429	(93)						
Series U	5.33	(0.12)	113	(3)						
Series U5	3.63	0.21	9	1						
Series UM	2.51	0.41	11,923	2,103						
Series LB	3.30	0.08	2,622	55						

2.75

2.35

0.43

0.10

7,016

11,653

861,344

855

462

73,994

Series LF

Series LW

Increase (decrease) in net assets attributable

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION

	To	tal	Series A		Series AR		Series CL		Series D	
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	4,800,747	4,648,584	946,652	967,183	106,772	96,460	9,025	6,150	8,258	6,658
Increase (decrease) in net assets from operations	861,344	73,994	155,183	3,562	18,427	1,000	800	388	3,022	141
Distributions paid to securityholders:										
Investment income	(27,390)	(20,383)	_	-	-	-	(167)	(106)	(120)	(26)
Capital gains	(2)	_		-	-	-	-	-	_	-
Return of capital	(101,799)	(101,864)	_	-	-	-	_	-	(723)	(392)
Management fee rebates	(113)	(116)	(51)	(52)				_		
Total distributions paid to securityholders	(129,304)	(122,363)	(51)	(52)	_	_	(167)	(106)	(843)	(418)
Security transactions:										
Proceeds from securities issued	1,391,937	908,384	348,144	224,013	28,336	21,470	2,110	6,167	14,784	2,502
Reinvested distributions	112,606	106,772	50	52	_	-	167	106	813	396
Payments on redemption of securities	(1,106,126)	(814,624)	(350,773)	(248, 106)	(20,393)	(12,158)	(11,935)	(3,680)	(3,485)	(1,021)
Total security transactions	398,417	200,532	(2,579)	(24,041)	7,943	9,312	(9,658)	2,593	12,112	1,877
Increase (decrease) in net assets attributable to securityholders	1,130,457	152,163	152,553	(20,531)	26,370	10,312	(9,025)	2,875	14,291	1,600
End of period	5,931,204	4,800,747	1,099,205	946,652	133,142	106,772		9,025	22,549	8,258
Increase (decrease) in fund securities (in thousands) (note 7):			Secur	ities	Secur	ities	Securit	ies	Securit	ties
Securities outstanding – beginning of period			34,527	35,457	4,751	4,313	526	365	408	315
Issued			12,009	8,591	1,192	1,004	117	383	717	125
Reinvested distributions			2	2	_	-	9	6	39	20
Redeemed			(12,107)	(9,523)	(853)	(566)	(652)	(228)	(166)	(52)
Securities outstanding – end of period			34,431	34,527	5,090	4,751	_	526	998	408

	Serie	es F	Series F8		Series	FB	Series	FB5	Series	1
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	938,794	792,297	12,189	12,325	3,562	3,149	33	32	719	603
Increase (decrease) in net assets from operations	198,014	21,259	2,793	174	595	76	6	2	130	18
Distributions paid to securityholders:										
Investment income	(9,208)	(5,182)	(133)	(67)	(19)	(12)	_	-	(4)	(2)
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	(52,127)	(45,161)	(1,195)	(1,029)	_	-	(2)	(2)	(37)	(36)
Management fee rebates	(5)	(5)				_				(2)
Total distributions paid to securityholders	(61,340)	(50,348)	(1,328)	(1,096)	(19)	(12)	(2)	(2)	(41)	(40)
Security transactions:										
Proceeds from securities issued	488,416	256,803	9,589	2,781	1,785	2,033	_	59	220	124
Reinvested distributions	50,527	40,666	393	294	19	12	2	2	39	36
Payments on redemption of securities	(188,200)	(121,883)	(3,826)	(2,289)	(2,076)	(1,696)	(1)	(60)	(180)	(22)
Total security transactions	350,743	175,586	6,156	786	(272)	349	1	1	79	138
Increase (decrease) in net assets attributable to securityholders	487,417	146,497	7,621	(136)	304	413	5	1	168	116
End of period	1,426,211	938,794	19,810	12,189	3,866	3,562	38	33	887	719
Increase (decrease) in fund securities (in thousands) (note 7):	Secur	ities	Securi	ties	Securit	ties	Secur	ties	Securit	ies
Securities outstanding – beginning of period	49,015	39,668	966	904	206	185	2	2	41	33
Issued	24,615	13,735	746	222	97	123	_	4	12	7
Reinvested distributions	2,569	2,205	31	24	1	1	_	_	2	2
Redeemed	(9,567)	(6,593)	(296)	(184)	(113)	(103)		(4)	(10)	(1)
Securities outstanding – end of period	66,632	49,015	1,447	966	191	206	2	2	45	41

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

	Series	i IG	Series J		Series 0		Series 05		Series PW	
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	_	-	20	19	816,558	936,619	2,477	2,439	1,267,346	1,183,545
Increase (decrease) in net assets from operations	114	-	3	1	144,193	17,142	475	72	223,620	13,482
Distributions paid to securityholders:										
Investment income	(13)	-	_	-	(12,679)	(10,520)	(42)	(31)	(1)	-
Capital gains	_	-	_	-	_	-	_	-	(2)	-
Return of capital	_	-	_	-	(38,203)	(44,852)	(124)	(128)	_	-
Management fee rebates									(47)	(47)
Total distributions paid to securityholders	(13)				(50,882)	(55,372)	(166)	(159)	(50)	(47)
Security transactions:										
Proceeds from securities issued	1,601	-	_	-	15,306	20,950	_	-	340,814	220,990
Reinvested distributions	13	-	_	-	50,580	55,141	166	159	50	47
Payments on redemption of securities	(1,714)				(126,568)	(157,922)	(44)	(34)	(214,300)	(150,671)
Total security transactions	(100)				(60,682)	(81,831)	122	125	126,564	70,366
Increase (decrease) in net assets attributable to securityholders	1		3	1	32,629	(120,061)	431	38	350,134	83,801
End of period	1_	_	23	20	849,187	816,558	2,908	2,477	1,617,480	1,267,346
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Secur	ities	Securit	ties	Secui	rities
Securities outstanding – beginning of period	_	-	1	1	41,186	45,466	122	116	57,697	54,358
Issued	151	-	_	-	739	1,081	_	-	14,597	10,584
Reinvested distributions	1	-	_	-	2,484	2,889	8	8	2	2
Redeemed	(152)				(6,184)	(8,250)	(2)	(2)	(9,288)	(7,247)
Securities outstanding – end of period		_	1	1	38,225	41,186	128	122	63,008	57,697

	Series PWFB		Series PV	Series PWFB5		Series PWR		Series PWT5		WT6
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	40,835	32,187	259	111	43,532	34,122	40,922	40,179	1,942	2,237
Increase (decrease) in net assets from operations	7,832	1,028	47	_	8,884	734	7,042	297	252	2
Distributions paid to securityholders:										
Investment income	(371)	(223)	(2)	(2)	_	_	_	_	_	_
Capital gains	_	-	_	-	_	-	_	_	_	-
Return of capital	_	_	(13)	(6)	_	_	(2,082)	(2,129)	(96)	(132)
Management fee rebates	(1)					_	(4)	(4)	(1)	(1)
Total distributions paid to securityholders	(372)	(223)	(15)	(8)		_	(2,086)	(2,133)	(97)	(133)
Security transactions:										
Proceeds from securities issued	12,734	12,334	10	243	20,492	11,080	7,074	5,336	_	-
Reinvested distributions	371	223	15	5	_	-	878	862	33	44
Payments on redemption of securities	(8,127)	(4,714)	(46)	(92)	(3,147)	(2,404)	(3,594)	(3,619)	(474)	(208)
Total security transactions	4,978	7,843	(21)	156_	17,345	8,676	4,358	2,579	(441)	(164)
Increase (decrease) in net assets attributable to securityholders	12,438	8,648	11	148	26,229	9,410	9,314	743	(286)	(295)
End of period	53,273	40,835	270	259	69,761	43,532	50,236	40,922	1,656	1,942
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securit	ies	Securi	ties	Securi	ties	Securit	ties
Securities outstanding – beginning of period	2,704	2,161	15	6	3,269	2,585	2,496	2,337	126	137
Issued	797	859	-	15	1,439	873	417	333	_	-
Reinvested distributions	23	15	1	-		-	52	55	2	3
Redeemed	(514)	(331)	(2)	(6)	(225)	(189)	(214)	(229)	(31)	(14)
Securities outstanding – end of period	3,010	2,704	14	15	4,483	3,269	2,751	2,496	97	126

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

	Series PWT8		Series PWX		Series PWX8		Series R		Series S	
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	38,566	34,631	24,741	30,482	2,010	2,143	230,169	218,751	20,037	19,267
Increase (decrease) in net assets from operations	6,411	540	4,499	327	364	51	34,570	9,804	3,660	553
Distributions paid to securityholders:										
Investment income	_	-	(397)	(332)	(32)	(26)	(3,000)	(2,987)	(314)	(242)
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	(3,139)	(3,169)	(1,199)	(1,421)	(156)	(177)	_	-	_	-
Management fee rebates	(1)	(1)				_				
Total distributions paid to securityholders	(3,140)	(3,170)	(1,596)	(1,753)	(188)	(203)	(3,000)	(2,987)	(314)	(242)
Security transactions:										
Proceeds from securities issued	5,340	9,116	4,487	2,532	25	37	13,482	42,726	2,556	2,217
Reinvested distributions	1,569	1,593	1,593	1,749	32	38	3,000	2,987	314	242
Payments on redemption of securities	(4,155)	(4,144)	(8,030)	(8,596)	(87)	(56)	(70,270)	(41,112)	(3,613)	(2,000)
Total security transactions	2,754	6,565	(1,950)	(4,315)	(30)	19	(53,788)	4,601	(743)	459
Increase (decrease) in net assets attributable to securityholders	6,025	3,935	953	(5,741)	146	(133)	(22,218)	11,418	2,603	770
End of period	44,591	38,566	25,694	24,741	2,156	2,010	207,951	230,169	22,640	20,037
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ities	Securi	ties	Securi	ties	Securi	ities	Securi	ties
Securities outstanding – beginning of period	2,467	2,040	1,126	1,336	130	128	13,428	12,982	762	745
Issued	335	591	199	117	1	3	744	2,794	91	88
Reinvested distributions	100	104	71	83	2	3	165	182	11	10
Redeemed	(264)	(268)	(352)	(410)	(5)	(4)	(4,013)	(2,530)	(132)	(81)
Securities outstanding – end of period	2,638	2,467	1,044	1,126	128	130	10,324	13,428	732	762

	Series T5		Series	T6	Series	T8	Series	U	Series U	5
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	23,837	27,118	5,026	5,705	16,671	19,760	784	1,109	67	68
Increase (decrease) in net assets from operations	3,896	(33)	747	(6)	2,429	(93)	113	(3)	9	1
Distributions paid to securityholders:										
Investment income	_	_	_	_	_	_	_	_	_	-
Capital gains	_	_	_	_	_	_	_	_	_	-
Return of capital	(1,184)	(1,322)	(284)	(344)	(1,232)	(1,560)	_	_	(3)	(4)
Management fee rebates	(1)	(1)			(2)	(3)			_	
Total distributions paid to securityholders	(1,185)	(1,323)	(284)	(344)	(1,234)	(1,563)			(3)	(4)
Security transactions:										
Proceeds from securities issued	7,946	3,980	63	354	3,736	4,842	_	-	-	-
Reinvested distributions	785	885	160	193	655	818	_	-	2	2
Payments on redemption of securities	(8,291)	(6,790)	(588)	(876)	(5,579)	(7,093)	(181)	(322)	(19)	
Total security transactions	440	(1,925)	(365)	(329)	(1,188)	(1,433)	(181)	(322)	(17)	2
Increase (decrease) in net assets attributable to securityholders	3,151	(3,281)	98	(679)	7	(3,089)	(68)	(325)	(11)	(1)
End of period	26,988	23,837	5,124	5,026	16,678	16,671	716	784	56	67
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securit	ies	Securit	ties	Securitie	:s
Securities outstanding – beginning of period	1,376	1,487	325	347	1,552	1,688	23	33	3	3
Issued	449	235	5	23	343	454	_	-	-	-
Reinvested distributions	44	53	10	13	61	78	-	-	-	-
Redeemed	(465)	(399)	(38)	(58)	(514)	(668)	(5)	(10)	(1)	l
Securities outstanding – end of period	1,404	1,376	302	325	1,442	1,552	18	23	2	3

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

	Series	UM	Series	Series LB		LF	Series LW	
	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS								
Beginning of period	81,800	67,801	14,323	13,644	34,315	26,133	68,506	65,657
Increase (decrease) in net assets from operations	11,923	2,103	2,622	55	7,016	855	11,653	462
Distributions paid to securityholders:								
Investment income	(575)	(453)	_	-	(313)	(172)	_	-
Capital gains	_	-	_	-	_	-	_	-
Return of capital	_	-	_	-	_	-	_	-
Management fee rebates		_		_		_		
Total distributions paid to securityholders	(575)	(453)		_	(313)	(172)		
Security transactions:								
Proceeds from securities issued	11,624	22,930	12,236	5,796	14,367	11,741	24,660	15,228
Reinvested distributions	67	48	_	-	313	172	_	-
Payments on redemption of securities	(31,240)	(10,629)	(8,922)	(5,172)	(5,958)	(4,414)	(20,310)	(12,841)
Total security transactions	(19,549)	12,349	3,314	624	8,722	7,499	4,350	2,387
Increase (decrease) in net assets attributable to securityholders	(8,201)	13,999	5,936	679	15,425	8,182	16,003	2,849
End of period	73,599	81,800	20,259	14,323	49,740	34,315	84,509	68,506
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securi	ties	Securi	ties
Securities outstanding – beginning of period	5,619	4,722	730	698	2,329	1,798	4,874	4,708
Issued	758	1,663	585	308	917	836	1,644	1,134
Reinvested distributions	4	3	_	-	20	12	_	-
Redeemed	(2,069)	(769)	(427)	(276)	(386)	(317)	(1,369)	(968)
Securities outstanding – end of period	4,312	5,619	888	730	2,880	2,329	5,149	4,874

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CASH FLOWS

for the periods ended March 31 (in \$ 000)

Cash flows from operating activities Net increase (decrease) in net assets attributable to securityholders from operations 861,344 73,994 Adjustments for:		2024 \$	2023 \$
securityholders from operations 861,344 73,994 Adjustments for: Net realized loss (gain) on investments (159,192) 19,035 Change in net unrealized loss (gain) on investments (676,541) (61,232) Distributions received in-kind from underlying funds (59) (323) Purchase of investments (1,164,073) (879,048) Proceeds from sale and maturity of investments 929,057 794,758 (Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (872,553) (661,709) Posteributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44)<	Cash flows from operating activities		
Adjustments for: Net realized loss (gain) on investments (159,192) 19,035 Change in net unrealized loss (gain) on investments (676,541) (61,232) Distributions received in-kind from underlying funds (59) (323) Purchase of investments (1,164,073) (879,048) Proceeds from sale and maturity of investments 929,057 794,758 (Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (872,553) (661,709) Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Eff	Net increase (decrease) in net assets attributable to		
Net realized loss (gain) on investments (159,192) 19,035 Change in net unrealized loss (gain) on investments (676,541) (61,232) Distributions received in-kind from underlying funds (59) (323) Purchase of investments (1,164,073) (879,048) Proceeds from sale and maturity of investments 929,057 794,758 (Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (872,553) (661,709) Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations	securityholders from operations	861,344	73,994
Change in net unrealized loss (gain) on investments (676,541) (61,232) Distributions received in-kind from underlying funds (59) (323) Purchase of investments (1,164,073) (879,048) Proceeds from sale and maturity of investments 929,057 794,758 (Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (213,420) (53,235) Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equival	•		
Distributions received in-kind from underlying funds (59) (323) Purchase of investments (1,164,073) (879,048) Proceeds from sale and maturity of investments 929,057 794,758 (Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (213,420) (53,235) Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash equivalents <td< td=""><td>•</td><td></td><td></td></td<>	•		
Purchase of investments (1,164,073) (879,048) Proceeds from sale and maturity of investments 929,057 794,758 (Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (872,553) (661,709) Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash 586 4,505 Cash and cash equivalents at end of period 180,833 129,759 Cash equivalents 180,247 125,254			
Proceeds from sale and maturity of investments 929,057 794,758 (Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (213,420) (53,235) Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operati	, 0	(,	,
(Increase) decrease in accounts receivable and other assets (4,386) 24 Increase (decrease) in accounts payable and other liabilities 430 (443) Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities (213,420) (53,235) Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash equivalents 180,247 125,254 Cash equivalents 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 114,876 <	Purchase of investments	. , ,	(879,048)
Net cash provided by (used in) operating activities	,		794,758
Net cash provided by (used in) operating activities (213,420) (53,235) Cash flows from financing activities 756,273 Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327			
Cash flows from financing activities Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	- ','		
Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	Net cash provided by (used in) operating activities	(213,420)	(53,235)
Proceeds from securities issued 1,153,712 756,273 Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327			
Payments on redemption of securities (872,553) (661,709) Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	<u> </u>		
Distributions paid net of reinvestments (16,698) (15,591) Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327			
Net cash provided by (used in) financing activities 264,461 78,973 Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	,		
Net increase (decrease) in cash and cash equivalents 51,041 25,738 Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327			
Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 114,876 12,753 Interest received 6,983 2,327	Net cash provided by (used in) financing activities	264,461	78,973
Cash and cash equivalents at beginning of period 129,759 104,065 Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: 112,158 105,823 Dividends received 114,876 12,753 Interest received 6,983 2,327			
Effect of exchange rate fluctuations on cash and cash equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327		<u>_</u>	
equivalents 33 (44) Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327		129,759	104,065
Cash and cash equivalents at end of period 180,833 129,759 Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	•	22	(44)
Cash 586 4,505 Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	<u> </u>		
Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	Cash and cash equivalents at end of period	180,833	129,759
Cash equivalents 180,247 125,254 Cash and cash equivalents at end of period 180,833 129,759 Supplementary disclosures on cash flow from operating activities: Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	Cash	586	4 505
Cash and cash equivalents at end of period180,833129,759Supplementary disclosures on cash flow from operating activities:Dividends received112,158105,823Foreign taxes paid14,87612,753Interest received6,9832,327		000	
Supplementary disclosures on cash flow from operating activities: Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327			
Dividends received 112,158 105,823 Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	outh and outh organizations at one of portou	100,000	120,700
Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327			
Foreign taxes paid 14,876 12,753 Interest received 6,983 2,327	Dividends received	112,158	105,823
Interest received 6,983 2,327	Foreign taxes paid		
·	•	,	
	Interest paid		•

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS

as at March 31, 2024

Abbil No. Abbi		Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
AbbVe Inc.	FOURTIES					
Air Liquide SA France United States Communication Services (78,667 and 13,152 128,730 and 13,152 128		11-21-101-1	II III - O	400.070	77.025	100 507
Alphabet Inc. Class A United States Communication Services 978,667 103,152 138,702 138,703						
Afrits Group Inc. Annadese IT Group SA Spain Consumer Biscretionary 488,675 4,864 53,346 Annazon.com Inc. United States Real States 106,831 2,341 28,346 120,931 169,740 Annalog Devices Inc. United States Real States 1106,831 23,343 38,856 Annazon.com Inc. United States Information Technology 18,827 34,323 38,856 Annalog Devices Inc. United States Information Technology 18,827 34,323 38,856 Annalog Devices Inc. United States Information Technology 18,827 34,323 38,856 Annalog Devices Inc. United States Information Technology 50,837 71,447 18,856 Anto Zene Inc. United States Information Technology 50,837 71,447 18,856 Anto Zene Inc. United States Health Care Anto Zene Inc. United States Information Technology 18,829 18,933 18,933 Anto Zene Inc. United States Health Care Anto Zene Inc. United States Information Technology 18,933 19,933 Anto Zene Inc. United States Information Technology 18,933 19,933 19,933 Anto Zene Inc. United States Information Technology 18,933 19,933 19,933 Anto Zene Inc. United States Information Technology 18,933 19,933 1	1			,	,	
Aradas Group SA Spain Consumer Discretionary 498,675 42,673 43,306 American Tower Corp. Class A United States Consumer Discretionary 54,8675 42,673 43,306 43,006	•					
Anazon.com Inc. United States Consumer Discretionary 694,880 120,931 169,749 Annelican Town Corp. Class A United States Relia Estate 10,631 23,841 23,841 23,841 23,841 23,841 28,450 38,855 38,855 38,855 38,855 38,855 39,135 99,050 48,827 34,320 38,855 38,955 38,855 38,955 38,955 39,135 99,050 48,865 49,000 48,865 48,865 30,900 39,135 99,505 48,855						
American Tower Corp. Class A United States Real Estate 106,317 23,431 28,450 Anna PLC Ireland Financials 200,234 59,135 99,056 Ann PLC United Mingdom Health Care \$20,024 59,135 99,056 Anna PLC United Mingdom Health Care \$20,023 59,135 99,056 48,261 41,455					,	
Analog Devices Inc. United States Information Technology 148,827 34,209 38,865 39,105						
Apn PLC Ireland Financials 200,254 59,135 99,505 Applied in Company 51,137 71,447 130,472 AstraZenea PLC United Kingdom Health Care \$25,038 95,533 95,835 95	•					
Apple Inc. United States Information Technology 561,817 71,447 130,472 AstarZance PLC United Kingdom Health Care 55,033 95,032 66,237 101,107 <					,	
AstzaReace PLC United Kingdom Altals Copco AB A Newden Altals Copco AB A Newden Altals Copco AB A Alta						
Altas Copo AB A Alta Copo AB						
AutoZeno Inc.					,	,
Becton, Dickinson and Co.	•					
Broadcom Inc.						
Chewron Corp.	·					
CME Group Inc. United States Financials 346,777 70,673 101,107 Colgate Palmolive Co. United States Consumer Staples 544,877 57,005 66,49 Compass Group PC United Klates Consumer Staples 544,877 57,005 66,49 Comoco-Phillips United Klates Consumer Staples 544,877 57,005 66,49 CRIR PLC United Klates Energy 345,475 48,244 59,50 CRIP PLC Including State Materials 19,15,660 59,122 69,234 Diage PLC United Kingdom Consumer Staples 792,840 37,666 39,649 Diage PLC United Kingdom Consumer Staples 792,840 37,66 39,649 Equifax Inc. United States United States United States 10,118 103,976 15,276 37,670 Equifax Inc. United States United States 10,128 43,054 53,030 Ferguson PLC (USD) United States Industrials 11,118 11			63			
The Consc-Cola Co. United States Consumer Staples 879,938 58,973 72,907 66,449 75,7005 66,449 75,7005 66,449 75,7005 66,449 75,7005 66,449 75,7005 66,449 75,7005 66,449 75,7005 66,449 75,7005 66,449 75,7005 66,449 75,7005 75,				,		
Colgate Palmolive Co. United States Consumer Staples 544,877 57,005 66,449 Compass Group PLC United States Consumer Discretionary 345,475 48,244 55,550 CORDER PLC Invited States Energy 345,475 48,244 55,550 DBS Group Holdings Ltd. Singapore Financials 1,915,660 59,122 62,234 Diago PLC United Kingdom Consumer Staples 792,840 37,766 38,640 Dike Energy Corp. United Kingdom Consumer Staples 792,840 37,766 38,640 Duke Energy Corp. United Kingdom Consumer Staples 285,788 36,613 37,430 Evolution Earming Group AB Sweden Consumer Dispress 65,887 11,718 11,09 Ferguson PC LUSD) United Kingdom Consumer Dispress 43,054 43,054 43,054 Gencore PLC Australia Materials 11,601,161 62,574 48,52,25 Haleon PLC United Kingdom Consumer Staples 11,718 41,099 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Compass Group PLC United Kingdom Consumer Discretionary 534,466 20,076 21,223 CRN PLC Ireland Materials 589,743 43,474 68,824 DBS Group Holdings Ltd. Singapore Financials 1,915,660 59,122 62,324 Deutsche Boerse AG Germany Financials 412,819 64,639 113,382 Diago PLC United Mingdom Consumer Staples 792,840 37,766 39,649 Duke Energy Corp. United States Unitual United States Unitual United States Unitual United States Unitual United States United States United States United States United States 1,152,76 37,670 Equitax Inc. United States Consumer Discretionary 68,897 11,718 11,099 Equitax Inc. United States United Mingdom Consumer Staples 16,897 11,718 11,099 11,718 11,099 11,718 11,099 11,718 11,099 11,718 11,099 11,718 11,099 11,000 10,000 10,000						
Conco-Phillips United States Energy 345,475 48,424 99,550 CRH PLC Ireland Mass and Materials 1,915,660 59,122 60,234 DBS Group Holdings Ltd. Singapore Financials 1,915,660 59,122 60,234 Diago PLC United Kingdom Consumer Staples 192,840 37,765 39,649 Duke Energy Corp. United States United States United States 10,181 10,3976 15,276 37,670 Equitax Inc. United States Consumer Discretionary 65,897 11,718 11,109 Ferguson PLC (USD) United States Industrials 179,266 43,064 53,030 Glencore PLC Australia Materials 11,701,161 62,747 86,325 Haleon PLC United Wingdom Consumer Staples 7,156,655 40,994 40,750 Haleon PLC United Kingdom Consumer Staples 7,156,655 40,994 40,750 Helicon PLC United States Industrials 11,501,161					,	
DRB Group Holdings t.t. Singapore Financials 1,915,660 59,122 69,234 Deutsche Boerse AG Germany Financials 1,915,660 59,122 69,234 Deutsche Boerse AG United Kingdom Consumer Staple 79,2840 37,766 36,643 Duke Energy Corp. United States Utilities 285,788 36,613 37,430 Equifax Inc. United States Utilities 285,788 36,613 37,430 Equifax Inc. United States Utilities 285,788 36,613 37,670 Equifax Inc. United States Industrials 103,976 15,276 37,670 Equifax Inc. United States Industrials 17,9266 43,054 53,030 Glencore PLC Australia Materials 1,601,161 62,574 85,325 Haleon PLC United Kingdom Consumer Staples 7,156,655 40,994 40,750 Hannover Ruckeversicherung SE Reg. Germany Financials 163,744 35,216 60,692 HDFC Bank Ltd. India Financials 2,072,427 45,554 48,735 Honeywell International Inc. United States Industrials 1,385,600 74,973 48,735 Honeywell International Inc. United States Industrials 1,385,600 74,973 49,101 HONE Group Changes and Clearing Ltd. Hong Kong Financials 1,385,600 74,973 49,101 HONE Group Changes Co. United States Health Care 483,387 91,301 103,558 HONE Group Changes Co. United States Health Care 483,387 91,301 103,558 Japan Exchange Group Inc. Japan Information Technology 62,566 25,271 38,925 Kweichow Moutai Co. Ltd. Class A China Consumer Staples 44,446 27,626 24,199 Honeywell Changes Co. United States Information Technology 62,566 25,271 38,925 Kweichow Moutai Co. Ltd. Class A China Consumer Staples 44,446 27,627 24,930 Light Medical Changes Co. United States Information Technology 62,566 25,271 38,925 Kweichow Moutai Co. Ltd. Class A United States Information Technology 62,566 25,271 38,925 Light Medical Changes Co. United States Information Technology 62,566 25,271 38,9					,	
DBS Group Holdings Ltd. Singapore (Germany Pinancials LAU 281) 59.122 69.234 Diageo PLC United Kingdom Consumer Staples 792.840 37.766 33 649 Duke Energy Corp. United States Utilities 285,788 36,613 37,430 Equifiax Inc. United States Utilities 285,788 36,613 37,430 Evolution Garning Group AB Sweden Consumer Discretionary 65,897 11,718 11,095 Erguson PLC Australia Materials 11,160,116 62,574 86,325 Haleon PLC United Kingdom Consumer Staples 7,156,655 40,994 40,756 Halor PLC United Kingdom Consumer Staples 7,156,65 40,994 40,756 Halor PLC United Kingdom Consumer Staples 7,156,65 40,994 40,756 Halor PLC United Kingdom Consumer Staples 7,156,65 40,994 40,750 Halor PLC United Kingdom Consumer Staples 338,322 38,814 36,972 <td< td=""><td></td><td></td><td></td><td></td><td>,</td><td></td></td<>					,	
Deutsche Boerse AG					,	
Diage PLC United Kingdom Consumer Staples 792,840 37,766 39,648 Duke Energy Corp. United States United States Industrials 103,976 11,278 37,430 Equitax Inc. United States Industrials 103,976 11,718 11,079 Evolution Gaming Group AB Sweden Consumer Discretionary 65,897 11,718 11,099 Ferguson PLC United States Industrials 11,601,161 62,574 86,325 Halenon PLC United Kingdom Consumer Staples 11,601,161 62,574 86,325 Hannover Rueckversicherung SE Reg. Germany Financials 1163,744 35,216 60,692 Heinreken Holding RV A Netherlands Consumer Staples 338,322 36,814 36,927 Hong Kong Exchanges and Clearing Ltd. Hong Kong Financials 1,027,427 45,554 48,735 Hong Kong Exchanges and Clearing Ltd. Hong Kong Financials 1,385,800 74,973 80,166 Japan Exchange Group Inc. Japan <t< td=""><td>, ,</td><td>.</td><td></td><td></td><td></td><td></td></t<>	, ,	.				
Duke Energy Corp. United States Utilities 285,788 36,613 37,430						
Equifax Inc.					,	
Evolution Gaming Group AB Sweden Consumer Discretionary 56,887 11,718 11,099 Ferguson PLC (USD) United States Materials 11,601,161 62,574 86,325 Maleon PLC United Kingdom Consumer Staples 7,156,655 40,994 40,750 Manower Rueckversicherung SE Reg. Germany Financials 163,744 35,216 60,692 MDFC Bank Ltd. India Financials 2,072,427 45,554 48,735 MDFC Bank Ltd. MDFC Bank Bank Bank Bank Bank Bank Bank Bank					,	
Ferguson PLC (USD)					,	
Gleincore PLC					,	
Haleon PLC					,	
Hannover Rueckversicherung SE Reg. Germany Financials 163,744 35,216 60,692 Hor Dank Ltd. India Financials 2,072,427 45,554 48,735 Heineken Holding NV A Netherlands Consumer Staples 338,322 36,814 36,972 Honeywell International Inc. United States Industrials 226,204 42,743 62,877 Hong Kong Exchanges and Clearing Ltd. Hong Kong Financials 614,084 27,626 62,877 Hong Kong Exchanges and Clearing Ltd. Hong Kong Financials 614,084 27,626 62,879 HOCHU Corp. Japan Industrials 1,385,800 74,973 80,166 Japan Exchange Group Inc. Japan Hondustrials 1,385,800 74,973 80,166 Japan Exchange Group Inc. Japan Hong States Health Care 433,387 91,301 103,558 JPMorgan Chase & Co. United States Health Care 433,387 91,301 103,558 JPMorgan Chase & Co. United States Health Care 433,387 91,301 103,558 JPMorgan Chase & Co. United States Health Care 433,387 91,301 103,558 JPMorgan Chase & Co. United States Information Technology 62,566 25,271 38,925 Keyence Corp. United States Information Technology 68,233 50,824 89,779 Linde PLC (New York Stock Exchange) Ireland Materials 99,143 22,833 62,343 London Stock Exchange Group PLC United Kingdom Materials 99,143 22,833 62,343 London Stock Exchange Group PLC United States Health Care 431,413 51,225 61,010 McKesson Corp. United States Health Care 341,413 51,225 61,010 Mctro & Co. Inc. United States Information Technology 52,3140 86,584 298,077 Motorola Solutions Inc. United States Information Technology 523,140 86,584 298,077 Motorola Solutions Inc. United States Information Technology 526,296 53,583 113,597 Motorola Solutions Inc. United States Information Technology 526,296 53,583 113,597 Motorola Solutions Inc. United States Information Technology 526,296 53,583 13,597 Motoro						
HDFC Bank Ltd.		•		, ,		
Heineken Holding NN A Netherlands Consumer Staples 338,322 36,814 36,972		,				
Honeywell International Inc.					,	
Hong Kong Exchanges and Clearing Ltd.						
TOČHU Corp. Japan Industrials 1,385,800 74,973 80,166 Japan Exchange Group Inc. Japan Financials 1,887,612 40,670 69,408 Johnson & United States Health Care 483,387 91,301 103,558 JPMorgan Chase & Co. United States Financials 612,348 94,382 166,107 Keyence Corp. Japan Information Technology 62,566 25,271 38,925 Lam Research Corp. United States Information Technology 68,233 50,824 89,779 Linde PLC (New York Stock Exchange) Ireland Materials 99,143 22,833 62,343 London Stock Exchange Group PLC United Kingdom Financials 93,778 14,405 15,213 LVMH Moet Hennessy Louis Vuitton SE France Consumer Discretionary 33,932 19,091 41,330 McDonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McKesson Corp. United States Health Care 103,391 53,349 75,170 McKesson Corp. United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Information Technology 523,140 86,584 298,072 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Motorola Solutions Inc. United States Information Technology 523,140 86,584 298,072 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 266,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 341,109 95,745 104,364 Rock Pollobal Inc. United States Financials Financials Financials 74,416 49,272 48,294 Novo Nordisk AS B Denmark Health Care 188,914 70,622 65,174 Philip Morris International Inc. United States Financials Finan						
Japan Exchange Group Inc. Japan Financials 1,887,612 40,670 69,408						,
Johnson & Johnson United States Health Care 483,387 91,301 103,558 JPMorgan Chase & Co. United States Health Care 486,387 94,382 166,107 Keyence Corp. Japan Information Technology 62,566 25,271 38,925 Kweichow Moutai Co. Ltd. Class A China Consumer Staples 46,446 2,970 14,809 Lam Research Corp. United States Information Technology 68,233 50,824 89,779 Linde PLC (New York Stock Exchange) Ireland Materials 99,143 22,833 62,343 Linde PLC (New York Stock Exchange) United Kingdom Financials 93,778 14,405 15,213 LIVMH Moet Hennessy Louis Vuitton SE France Consumer Discretionary 33,932 19,091 41,330 McDonald's Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Information Technology 523,140 86,584 298,023 Moody's Corp. United States Information Technology 523,140 86,584 298,023 Moody's Corp. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Information Technology 262,698 40,446 Oracle Corp. Uni		•				
JPMorgan Chase & Co. United States Financials Information Technology 612,348 94,382 166,107 Keyence Corp. Keyence Corp. Japan Information Technology 62,566 25,271 38,925 Kweichow Moutai Co. Ltd. Class A China Consumer Staples 46,446 2,970 14,809 Lam Research Corp. United States Information Technology 68,233 50,824 89,779 Linde PLC (New York Stock Exchange) I reland Materials 99,143 22,833 62,343 London Stock Exchange Group PLC United Kingdom France Consumer Discretionary 33,932 19,091 41,330 MCP Metham Change Sp Louis Vuitton SE France Consumer Discretionary 162,351 34,791 61,992 McPonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McResson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Communication Services 190,204 85,023 125,080					,	
Keyence Corp. Japan (China) Information Technology (China) 62,566 (China) 25,271 (China) 38,925 (China) Kweichow Moutai Co. Ltd. Class A (China) Consumer Staples (China) 46,446 (China) 2,970 (China) 14,809 (China) Lam Research Corp. United States (Information Technology (China) 68,233 (China) 50,824 (China) 89,778 (China) 30,824 (China) 89,743 (China) 22,833 (China) 62,343 (China) 62,443 (China) 62,614 (China) 62,614 (China) 62,614 (China						
Kweichow Moutai Co. Ltd. Class A China Lam Research Corp. United States Consumer Staples 46,446 2,970 14,809 Lam Research Corp. United States Information Technology 68,233 50,824 89,779 Linde PLC (New York Stock Exchange) Ireland Materials 99,143 22,833 62,343 London Stock Exchange Group PLC United Kingdom Financials 93,778 14,405 15,213 LVMH Moet Hennessy Louis Vuitton SE France Consumer Discretionary 33,932 19,091 41,330 McDonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McKesson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 M						
Lam Research Corp. United States Information Technology 68,233 50,824 89,779 Linde PLC (New York Stock Exchange) Ireland Materials 99,143 22,833 62,343 London Stock Exchange Group PLC United Kingdom Financials 93,778 14,405 15,213 LVMH Moet Hennessy Louis Vuitton SE France Consumer Discretionary 33,932 19,091 41,330 McDonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McKesson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Met Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Moody's Corp. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland			•			
Linde PLC (New York Stock Exchange) Ireland Materials 99,143 22,833 62,343 London Stock Exchange Group PLC United Kingdom Financials 93,778 14,405 15,213 LVMH Moet Hennessy Louis Vuitton SE France Consumer Discretionary 33,932 19,091 41,330 McDonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McKesson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Moody's Corp. United States Information Technology 50,307 9,221 26,777 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States						
London Stock Exchange Group PLC United Kingdom Financials 93,778 14,405 15,213 LVMH Moet Hennessy Louis Vuitton SE France Consumer Discretionary 33,932 19,091 41,330 McDonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McKesson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Modry's Corp. United States Information Technology 53,249 53,583 113,597 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Novo Nordisk AS B Denmark						
LVMH Moet Hennessy Louis Vuitton SE France Consumer Discretionary 33,932 19,091 41,330 McDonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McKesson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Moody's Corp. United States Information Technology 523,140 86,584 298,072 Moody's Corp. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology						
McDonald's Corp. United States Consumer Discretionary 162,351 34,791 61,992 McKesson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Met Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Modry's Corp. United States Information Technology 523,140 86,584 298,072 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology						
McKesson Corp. United States Health Care 103,391 53,349 75,170 Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Met Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Modory's Corp. United States Financials 50,307 9,221 26,777 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433						
Merck & Co. Inc. United States Health Care 341,413 51,225 61,010 Meta Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Moody's Corp. United States Financials 50,307 9,221 26,777 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. Denmark Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples						
Meta Platforms Inc. Class A United States Communication Services 190,204 85,023 125,080 Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Moody's Corp. United States Financials 50,307 9,221 26,777 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care						
Microsoft Corp. United States Information Technology 523,140 86,584 298,072 Moody's Corp. United States Financials 50,307 9,221 26,777 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669						
Moody's Corp. United States Financials 50,307 9,221 26,777 Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481<						
Motorola Solutions Inc. United States Information Technology 236,296 53,583 113,597 Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890	•					
Nestlé SA Reg. Switzerland Consumer Staples 344,824 37,859 49,589 Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890						
Northrop Grumman Corp. United States Industrials 74,416 49,272 48,239 Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890						49.589
Novo Nordisk AS B Denmark Health Care 625,954 22,850 108,051 Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890	•					
Oracle Corp. United States Information Technology 262,698 40,344 44,688 Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890						
Pernod Ricard SA France Consumer Staples 119,433 23,084 26,165 Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890						
Philip Morris International Inc. United States Consumer Staples 841,109 95,745 104,364 Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890						
Roche Holding AG Genusscheine Switzerland Health Care 188,914 70,622 65,174 S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890					,	
S&P Global Inc. United States Financials 135,669 60,278 78,170 Safran SA France Industrials 289,656 39,481 88,890	•				,	
Safran SA France Industrials 289,656 39,481 88,890						
VOLDA GERMAN MINIMARION (CONTINUES 033.37.3 107.7.53 1.04.347	SAP AG	Germany	Information Technology	699,973	102,235	184,547

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS (cont'd)

as at March 31, 2024

	Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
	Country	360101	Silaies/Oilles	(φ 000)	(φ 000)
EQUITIES (cont'd)					
Schlumberger Ltd.	United States	Energy	524,511	29,119	38,933
Shell PLC (GBP Shares)	Netherlands	Energy	2,316,032	85,953	103,925
The Sherwin-Williams Co.	United States	Materials	78,054	13,286	36,715
Siemens AG	Germany	Industrials	234,234	54,089	60,558
Sika AG	Switzerland	Materials	68,149	13,037	27,493
Sony Corp.	Japan	Consumer Discretionary	519,492	39,347	60,350
Starbucks Corp.	United States	Consumer Discretionary	273,779	25,650	33,885
Taiwan Semiconductor Manufacturing Co. Ltd.	Taiwan	Information Technology	3,000,259	41,821	98,907
Texas Instruments Inc.	United States	Information Technology	128,543	19,137	30,327
Thales SA	France	Industrials	147,044	29,890	33,954
Thermo Fisher Scientific Inc.	United States	Health Care	61,719	43,823	48,580
Union Pacific Corp.	United States	Industrials	213,168	59,542	70,997
UnitedHealth Group Inc.	United States	Health Care	113,067	79,937	75,751
Veolia Environnement	France	Utilities	872,592	37,056	38,411
Visa Inc. Class A	United States	Financials	245,278	45,091	92,703
The Williams Companies Inc.	United States	Energy	1,432,904	60,300	75,623
Wolters Kluwer NV	Netherlands	Industrials	248,943	25,223	52,810
Total equities			-	3,846,220	5,724,360
MUTUAL FUNDS					
 Mackenzie International Dividend Fund Series R 	Canada	Mutual Funds	1,686,919	19,111	26,181
Total mutual funds			-	19,111	26,181
Transaction costs				(5,734)	_
Total investments			-	3,859,597	5,750,541
Derivative instruments					
(see schedule of derivative instruments)					1,479
• • • • • • • • • • • • • • • • • • • •					
Cash and cash equivalents Other assets less liabilities					180,833 (1,649)
				_	
Net assets attributable to securityholders				_	5,931,204

 $^{^{1}\,\,}$ The issuer of this security is related to Mackenzie. See Note 1. $^{2}\,\,$ This fund is managed by Mackenzie.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SUMMARY OF INVESTMENT PORTFOLIO

PORTFOLIO ALLOCATION

MARCH 31, 2024

MARCH 31, 2023

% of NAV

96.7

Cash and cash equivalents	3.1	Cash and short-term investments	2.7
Mutual funds	0.4	Mutual funds Other assets (liabilities)	0.9 (0.3)
REGIONAL ALLOCATION	% OF NAV	REGIONAL ALLOCATION	% OF NAV
United States	58.1	United States	57.2
Germany	7.1	Germany	5.8
France	4.9	Switzerland	5.8
Japan	4.2	Netherlands	4.8
Ireland	3.7	France	4.8
United Kingdom	3.6	Japan	3.8
Netherlands	3.3	United Kingdom	2.8
Cash and cash equivalents	3.1	Ireland	2.8
Switzerland	2.4	Cash and short-term investments	2.7
Other	1.8	Hong Kong	1.7
Denmark	1.8	Denmark	1.6
Taiwan	1.7	Other	1.5
Australia	1.5	Spain	1.3
Singapore	1.2	Singapore	1.3
India	0.8	Taiwan	1.3
Sweden	0.8	Canada	0.9
		Other assets (liabilities)	(0.3)

% of NAV

96.5

PORTFOLIO ALLOCATION

SECTOR ALLOCATION	% OF NAV	SECTOR ALLOCATION	% OF NAV
Information technology	20.8	Financials	17.2
Financials	16.1	Information technology	17.0
Health care	13.8	Health care	16.3
Industrials	10.5	Consumer staples	12.1
Consumer staples	8.5	Industrials	8.1
Consumer discretionary	8.3	Energy	7.7
Energy	6.5	Consumer discretionary	7.7
Materials	5.8	Materials	7.2
Communication services	4.4	Cash and short-term investments	2.7
Cash and cash equivalents	3.1	Communication services	2.5
Utilities	1.3	Real estate	0.9
Real estate	0.5	Mutual funds	0.9
Mutual funds	0.4	Other assets (liabilities)	(0.3)

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF DERIVATIVE INSTRUMENTS

as at March 31, 2024

Counterparty Credit Rating		cy to be d (\$ 000)	Currency Delivered		Settlement Date	Contract Cost (\$ 000)	Current Fair Value (\$ 000)	Unrealized Gains (\$ 000)	Unrealized Losses (\$ 000)
Α	27,878	CAD	(17,608)	CHF	Apr. 17, 2024	(27,878)	(26,492)	1,386	_
Α	940	CHF	(1,488)	CAD	Apr. 17, 2024	1,488	1,414	_	(74
Α	1,310	CHF	(2,043)	CAD	Apr. 17, 2024	2,043	1,971	_	(72
Α	990	CHF	(1,533)	CAD	Apr. 17, 2024	1,533	1,490	_	(43
Α	2,968	CAD	(1,930)	CHF	Apr. 17, 2024	(2,968)	(2,904)	64	_
Α	16,298	CHF	(25,066)	CAD	Apr. 17, 2024	25,066	24,519	_	(547
Α	30,151	CAD	(17,703)	GBP	Apr. 17, 2024	(30,151)	(30,260)	_	(109
Α	22,213	CAD	(13,042)	GBP	Apr. 17, 2024	(22,213)	(22,293)	_	(80
Α	4,214	CAD	(2,460)	GBP	Apr. 17, 2024	(4,214)	(4,205)	9	_
Α	68,964	CAD	(46,943)	EUR	Apr. 19, 2024	(68,964)	(68,631)	333	-
Α	113,684	CAD	(77,344)	EUR	Apr. 19, 2024	(113,684)	(113,077)	607	-
Α	4,368	CAD	(3,000)	EUR	Apr. 19, 2024	(4,368)	(4,386)	_	(18
Α	9,487	CAD	(6,490)	EUR	Apr. 19, 2024	(9,487)	(9,488)	_	(1
Α	10,114	CAD	(6,900)	EUR	Apr. 26, 2024	(10,114)	(10,090)	24	-
l forward currency	contracts							2,423	(944
al Derivative assets	;								2,423
al Derivative liabilit	ies								(944)

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

1. Fiscal Periods and General Information

The information provided in these financial statements and notes thereto is for the periods ended or as at March 31, 2024 and 2023, as applicable. In the year a Fund or series is established or reinstated, 'period' represents the period from inception or reinstatement. Where a series of a Fund was terminated during either period, the information for the series is provided up to close of business on the termination date. Refer to Note 10 for the formation date of the Fund and the inception date of each series.

The Fund is organized as an open-ended mutual fund trust established under the laws of the Province of Ontario pursuant to a Declaration of Trust as amended and restated from time to time. The address of the Fund's registered office is 180 Queen Street West, Toronto, Ontario, Canada. The Fund is authorized to issue an unlimited number of units (referred to as "security" or "securities") of multiple series. Series of the Fund are available for sale under Simplified Prospectus or exempt distribution options.

Mackenzie Financial Corporation ("Mackenzie") is the manager of the Fund and is wholly owned by IGM Financial Inc., a subsidiary of Power Corporation of Canada. Canada Life Investment Management Ltd. ("CLIML") is wholly owned by The Canada Life Assurance Company ("Canada Life"), a subsidiary of Power Corporation of Canada. Investments in companies within the Power Group of companies held by the Fund are identified in the Schedule of Investments.

2. Basis of Preparation and Presentation

These audited annual financial statements ("financial statements") have been prepared in accordance with IFRS Accounting Standards ("IFRS"). A summary of the Fund's material accounting policies under IFRS is presented in Note 3.

These financial statements are presented in Canadian dollars, which is the Fund's functional and presentation currency, and rounded to the nearest thousand unless otherwise indicated. These financial statements are prepared on a going concern basis using the historical cost basis, except for financial instruments that have been measured at fair value.

These financial statements were authorized for issue by the Board of Directors of Mackenzie Financial Corporation on June 4, 2024.

3. Material Accounting Policies

The Fund adopted Disclosure of Accounting Policies Amendments to IAS 1 and IFRS Practice Statements 2 from April 1, 2023. Although the amendments did not result in any changes to the accounting policies themselves, they impacted the accounting policy information disclosed in the financial statements. The amendments require the disclosure of 'material' rather than 'significant' accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies. The Manager reviewed the accounting policies and made updates to the information disclosed in certain instances in line with the amendments.

(a) Financial instruments

Financial instruments include financial assets and liabilities such as debt and equity securities, investment funds and derivatives. The Fund classifies and measures financial instruments in accordance with IFRS 9, *Financial Instruments* ("IFRS 9"). Upon initial recognition, financial instruments are classified as fair value through profit or loss ("FVTPL"). All financial instruments are recognized in the Statement of Financial Position when the Fund becomes a party to the contractual requirements of the instrument. Financial assets are derecognized when the right to receive cash flows from the instrument has expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation is discharged, cancelled or expires. Investment purchase and sale transactions are recorded as of the trade date.

Financial instruments are subsequently measured at FVTPL with changes in fair value recognized in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The cost of investments is determined on a weighted average cost basis.

Realized and unrealized gains and losses on investments are calculated based on the weighted average cost of investments and exclude commissions and other portfolio transaction costs, which are separately reported in the Statement of Comprehensive Income — Commissions and other portfolio transaction costs.

Gains and losses arising from changes in the fair value of the investments are included in the Statement of Comprehensive Income for the period in which they arise.

The Fund accounts for its holdings in unlisted open-ended investment funds, private funds ("Underlying Funds") and Exchange-Traded Funds ("ETFs"), if any, at FVTPL. For private funds, the Manager will rely on the valuations provided by the managers of the private funds, which represents the Fund's proportionate share of the net assets of these private funds. The Fund's investment in Underlying Funds and ETFs, if any, is presented in the Schedule of Investments at fair value which represents the Fund's maximum exposure on these investments.

The Fund's redeemable securities contain multiple dissimilar contractual obligations and entitle securityholders to the right to redeem their interest in the Fund for cash equal to their proportionate share of the net asset value of the Fund and therefore meet the criteria for classification as financial liabilities under IAS 32 Financial Instruments: Presentation. The Fund's obligation for net assets attributable to securityholders is presented at the redemption amount.

IAS 7, Statement of Cash Flows, requires disclosures related to changes in liabilities and assets, such as the securities of the Fund, arising from financing activities. Changes in securities of the Fund, including both changes from cash flows and non-cash changes, are included in the Statement of Changes in Financial Position. Any changes in the securities not settled in cash as at the end of the period are presented as either Accounts receivable for securities issued or Accounts payable for securities redeemed in the Statement of Financial Position. These accounts receivable and accounts payable amounts typically settle shortly after period-end.

(b) Fair value measurement

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(b) Fair value measurement (cont'd)

Investments listed on a public securities exchange or traded on an over-the-counter market are valued on the basis of the last traded market price or closing price recorded by the security exchange on which the security is principally traded, where this price falls within the quoted bid-ask spread for the investment. In circumstances where this price is not within the bid-ask spread, Mackenzie determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. Mutual fund securities of an underlying fund are valued on a business day at the price calculated by the manager of such underlying fund in accordance with the constating documents of such underlying fund. Unlisted or non-exchange traded investments, or investments where a last sale or close price is unavailable or investments for which market quotations are, in Mackenzie's opinion, inaccurate, unreliable, or not reflective of all available material information, are valued at their fair value as determined by Mackenzie using appropriate and accepted industry valuation techniques including valuation models. The fair value determined using valuation models requires the use of inputs and assumptions based on observable market data including volatility and other applicable rates or prices. In limited circumstances, the fair value may be determined using valuation techniques that are not supported by observable market data.

Cash and cash equivalents which includes cash on deposit with financial institutions and short-term investments that are readily convertible to cash, are subject to an insignificant risk of changes in value, and are used by the Fund in the management of short-term commitments. Cash and cash equivalents are reported at fair value which closely approximates their amortized cost due to their nature of being highly liquid and having short terms to maturity. Bank overdraft positions are presented under current liabilities as bank indebtedness in the Statement of Financial Position.

The Fund may use derivatives (such as written options, futures, forward contracts, swaps or customized derivatives) to hedge against losses caused by changes in securities prices, interest rates or exchange rates. The Fund may also use derivatives for non-hedging purposes in order to invest indirectly in securities or financial markets, to gain exposure to other currencies, to seek to generate additional income, and/or for any other purpose considered appropriate by the Fund's portfolio manager(s), provided that the use of the derivative is consistent with the Fund's investment objectives. Any use of derivatives will comply with Canadian mutual fund laws, subject to the regulatory exemptions granted to the Fund, as applicable.

Valuations of derivative instruments are carried out daily, using normal exchange reporting sources for exchange-traded derivatives and specific broker enquiry for over-the-counter derivatives.

The value of forward contracts is the gain or loss that would be realized if, on the valuation date, the positions were to be closed out. The change in value of forward contracts is included in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The daily fluctuation of futures contracts or swaps, along with daily cash settlements made by the Fund, where applicable, are equal to the change in unrealized gains or losses that are best determined at the settlement price. These unrealized gains or losses are recorded and reported as such until the Fund closes out the contract or the contract expires. Margin paid or deposited in respect of futures contracts or swaps is reflected as a receivable in the Statement of Financial Position — Margin on derivatives. Any change in the variation margin requirement is settled daily.

Premiums paid for purchasing an option are recorded in the Statement of Financial Position – Investments at fair value.

Premiums received from writing options are included in the Statement of Financial Position as a liability and subsequently adjusted daily to fair value. If a written option expires unexercised, the premium received is recognized as a realized gain. If a written call option is exercised, the difference between the proceeds of the sale plus the value of the premium, and the cost of the security is recognized as a realized gain or loss. If a written put option is exercised, the cost of the security acquired is the exercise price of the option less the premium received.

Refer to the Schedule of Derivative Instruments and Schedule of Options Purchased/Written, as applicable, included in the Schedule of Investments for a listing of derivative and options positions as at March 31, 2024.

The Fund categorizes the fair value of its assets and liabilities into three categories, which are differentiated based on the observable nature of the inputs and extent of estimation required.

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly. Examples of Level 2 valuations include quoted prices for similar securities, quoted prices on inactive markets and from recognized investment dealers, and the application of factors derived from observable data to non-North American quoted prices in order to estimate the impact of differences in market closing times.

Financial instruments classified as Level 2 investments are valued based on the prices provided by an independent reputable pricing services company who prices the securities based on recent transactions and quotes received from market participants and through incorporating observable market data and using standard market convention practices. Short-term investments classified as Level 2 investments are valued based on amortized cost plus accrued interest which closely approximates fair value.

The estimated fair values for these securities may be different from the values that would have been used had a ready market for the investment existed; and Level 3 – Inputs that are not based on observable market data.

The inputs are considered observable if they are developed using market data, such as publicly available information about actual events or transactions, and that reflect the assumption that market participants would use when pricing the asset or liability.

See Note 10 for the fair value classifications of the Fund.

(c) Income recognition

Interest income for distribution purposes represents the coupon interest received by the Fund which is accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds, which are amortized on a straight-line basis. Dividends are accrued as of the ex-dividend date. Unrealized gains or losses on investments, realized gains or losses on the sale of investments, including foreign exchange gains or losses on such investments, are calculated on a weighted average cost basis. Distributions received from an underlying fund are included in interest income, dividend income, realized gains (losses) on sale of investments or fee rebate income, as appropriate, on the ex-dividend or distribution date.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(c) Income recognition (cont'd)

Income, realized gains (losses) and unrealized gains (losses) are allocated daily among the series on a pro-rata basis.

(d) Commissions and other portfolio transaction costs

Commissions and other portfolio transaction costs are costs incurred to acquire, issue or dispose of financial assets or liabilities. They include fees and commissions paid to agents, exchanges, brokers, dealers and other intermediaries. The total brokerage commissions incurred by the Fund in connection with portfolio transactions for the periods, together with other transaction charges, is disclosed in the Statements of Comprehensive Income. Brokerage business is allocated to brokers based on the best net result for the Fund. Subject to this criteria, commissions may be paid to brokerage firms which provide (or pay for) certain services, other than order execution, which may include investment research, analysis and reports, and databases or software in support of these services. Where applicable and ascertainable, the value of these services generated during the periods is disclosed in Note 10. The value of certain proprietary services provided by brokers cannot be reasonably estimated.

(e) Securities lending, repurchase and reverse repurchase transactions

The Fund is permitted to enter into securities lending, repurchase and reverse repurchase transactions as set out in the Fund's Simplified Prospectus. These transactions involve the temporary exchange of securities for collateral with a commitment to redeliver the same securities on a future date.

Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on cash or securities held as collateral. Income earned from these transactions is included in the Statement of Comprehensive Income and recognized when earned. Securities lending transactions are administered by The Bank of New York Mellon (the "Securities Lending Agent"). The value of cash or securities held as collateral must be at least 102% of the fair value of the securities loaned, sold or purchased.

Note 10 summarizes the details of securities loaned and collateral received as at the end of period, as well as a reconciliation of securities lending income during the period, if applicable. Collateral received is comprised of debt obligations of the Government of Canada and other countries, Canadian provincial and municipal governments, and financial institutions.

(f) Offsetting

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position only when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously. In the normal course of business, the Fund enters into various master netting agreements or similar agreements that do not meet the criteria for offsetting in the Statement of Financial Position but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or termination of the contracts. Note 10 summarizes the details of such offsetting, if applicable, subject to master netting arrangements or other similar agreements and the net impact to the Statements of Financial Position if all such rights were exercised.

Income and expenses are not offset in the Statement of Comprehensive Income unless required or permitted to by an accounting standard, as specifically disclosed in the IFRS policies of the Fund.

(g) Currency

The functional and presentation currency of the Fund is Canadian dollars. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated to Canadian dollars at the rate of exchange prevailing at the time of the transactions.

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net realized gain (loss).

The fair value of investments and other assets and liabilities, denominated in foreign currencies, are translated to Canadian dollars at the rate of exchange prevailing on each business day.

(h) Net assets attributable to securityholders per security

Net assets attributable to securityholders per security is computed by dividing the net assets attributable to securityholders of a series of securities on a business day by the total number of securities of the series outstanding on that day.

(i) Net asset value per security

The daily Net Asset Value ("NAV") of an investment fund may be calculated without reference to IFRS as per the Canadian Securities Administrators' ("CSA") regulations. The difference between NAV and Net assets attributable to securityholders (as reported in the financial statements), if any, is mainly due to differences in fair value of investments and other financial assets and liabilities and is disclosed in Note 10.

(j) Increase (decrease) in net assets attributable to securityholders from operations per security

Increase (decrease) in net assets attributable to securityholders from operations per security in the Statement of Comprehensive Income represents the increase (decrease) in net assets attributable to securityholders from operations for the period, divided by the weighted average number of securities outstanding during the period.

(k) Mergers

In a fund merger, the Fund acquires all of the assets and assumes all of the liabilities of the terminating fund at fair value in exchange for securities of the Fund on the effective date of the merger.

(I) Future accounting changes

The Fund has determined there are no material implications to the Fund's financial statements arising from IFRS issued but not yet effective.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

4. Critical Accounting Estimates and Judgments

The preparation of these financial statements requires management to make estimates and assumptions that primarily affect the valuation of investments. Estimates and assumptions are reviewed on an ongoing basis. Actual results may differ from these estimates.

The following discusses the most significant accounting judgments and estimates made in preparing the financial statements:

Use of Estimates

Fair value of securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets and are valued using valuation techniques that make use of observable data, to the extent practicable. Various valuation techniques are utilized, depending on a number of factors, including comparison with similar instruments for which observable market prices exist and recent arm's length market transactions. Key inputs and assumptions used are company specific and may include estimated discount rates and expected price volatilities. Changes in key inputs, could affect the reported fair value of these financial instruments held by the Fund.

Use of Judgments

Classification and measurement of investments

In classifying and measuring financial instruments held by the Fund, Mackenzie is required to make significant judgments in order to determine the most appropriate classification in accordance with IFRS 9. Mackenzie has assessed the Fund's business model, the manner in which all financial instruments are managed and performance evaluated as a group on a fair value basis, and concluded that FVTPL in accordance with IFRS 9 provides the most appropriate measurement and presentation of the Fund's financial instruments.

Functional currency

The Fund's functional and presentation currency is the Canadian dollar, which is the currency considered to best represent the economic effects of the Fund's underlying transactions, events and conditions taking into consideration the manner in which securities are issued and redeemed and how returns and performance by the Fund are measured.

Interest in unconsolidated structured entities

In determining whether an Underlying Fund or an ETF in which the Fund invests, but that it does not consolidate, meets the definition of a structured entity, Mackenzie is required to make significant judgments about whether these underlying funds have the typical characteristics of a structured entity. These Underlying Funds do meet the definition of a structured entity because:

I. The voting rights in the Underlying Funds are not dominant factors in deciding who controls them;

II. the activities of the Underlying Funds are restricted by their offering documents; and

III. the Underlying Funds have narrow and well-defined investment objectives to provide investment opportunities for investors while passing on the associated risks and rewards.

As a result, such investments are accounted for at FVTPL. Note 10 summarizes the details of the Fund's interest in these Underlying Funds, if applicable.

5. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and, accordingly, is subject to tax on its income including net realized capital gains in the taxation year, which is not paid or payable to its securityholders as at the end of the taxation year. The Fund maintains a December year-end for tax purposes. The Fund may be subject to withholding taxes on foreign income. In general, the Fund treats withholding tax as a charge against income for tax purposes. The Fund will distribute sufficient amounts from net income for tax purposes, as required, so that the Fund will not pay income taxes other than refundable tax on capital gains, if applicable.

Losses of the Fund cannot be allocated to investors and are retained in the Fund for use in future years. Non-capital losses may be carried forward up to 20 years to reduce taxable income and realized capital gains of future years. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Refer to Note 10 for the Fund's loss carryforwards.

6. Management Fees and Operating Expenses

Mackenzie is paid a management fee for managing the investment portfolio, providing investment analysis and recommendations, making investment decisions, making brokerage arrangements relating to the purchase and sale of the investment portfolio and making arrangements with registered dealers for the purchase and sale of securities of the Fund by investors. The management fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Each series of the Fund, except B-Series, is charged a fixed rate annual administration fee ("Administration Fee") and in return, Mackenzie bears all of the operating expenses of the Fund, other than certain specified fund costs. The Administration Fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Other fund costs include taxes (including, but not limited to GST/HST and income tax), interest and borrowing costs, all fees and expenses of the Mackenzie Funds' Independent Review Committee (IRC), costs of complying with the regulatory requirement to produce Fund Facts, fees paid to external service providers associated with tax reclaims, refunds or the preparation of foreign tax reports on behalf of the Funds, new fees related to external services that were not commonly charged in the Canadian mutual fund industry and introduced after the date of the most recently filed simplified prospectus, and the costs of complying with any new regulatory requirements, including, without limitation, any new fees introduced after the date of the most recently filed simplified prospectus.

All expenses relating to the operation of the Fund attributable to B-Series securities will be charged to that particular series. Operating expenses include legal, audit, transfer agent, custodian, administration and trustee services, cost of financial reporting and Simplified Prospectus printing, regulatory filing fees and other miscellaneous expenses specifically attributable to the B-Series securities and any applicable taxes.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

6. Management Fees and Operating Expenses (cont'd)

Mackenzie may waive or absorb management fees and/or Administration Fees at its discretion and stop waiving or absorbing such fees at any time without notice. Refer to Note 10 for the management fee and Administration Fee rates charged to each series of securities.

7. Fund's Capital

The capital of the Fund, which is comprised of the net assets attributable to securityholders, is divided into different series with each series having an unlimited number of securities. The securities outstanding for the Fund as at March 31, 2024 and 2023 and securities issued, reinvested and redeemed for the periods are presented in the Statement of Changes in Financial Position. Mackenzie manages the capital of the Fund in accordance with the investment objectives as discussed in Note 10.

8. Financial Instruments Risk

i. Risk exposure and management

The Fund's investment activities expose it to a variety of financial risks, as defined in IFRS 7, *Financial Instruments: Disclosures* ("IFRS 7"). The Fund's exposure to financial risks is concentrated in its investments, which are presented in the Schedule of Investments, as at March 31, 2024, grouped by asset type, with geographic and sector information.

Mackenzie seeks to minimize potential adverse effects of financial risks on the Fund's performance by employing professional, experienced portfolio advisors, by monitoring the Fund's positions and market events daily, by diversifying the investment portfolio within the constraints of the Fund's investment objectives, and where applicable, by using derivatives to hedge certain risk exposures. To assist in managing risks, Mackenzie also maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy, internal guidelines, and securities regulations.

ii. Liquidity risk

Liquidity risk arises when the Fund encounters difficulty in meeting its financial obligations as they become due. The Fund is exposed to liquidity risk due to potential daily cash redemptions of redeemable securities. In order to monitor the liquidity of its assets, the Fund utilizes a liquidity risk management program that calculates the number of days to convert the investments held by the Fund into cash using a multi-day liquidation approach. This liquidity risk analysis assesses the Fund's liquidity against predetermined minimum liquidity percentages established for different time periods and is monitored quarterly. In addition, the Fund has the ability to borrow up to 5% of its net assets for the purposes of funding redemptions.

In order to comply with securities regulations, the Fund must maintain at least 85% of its assets in liquid investments (i.e., investments that can be readily sold).

iii. Currency risk

Currency risk is the risk that financial instruments which are denominated or exchanged in a currency other than the Canadian dollar, which is the Fund's functional currency, will fluctuate due to changes in exchange rates. Generally, foreign denominated investments increase in value when the value of the Canadian dollar (relative to foreign currencies) falls. Conversely, when the value of the Canadian dollar rises relative to foreign currencies, the values of foreign denominated investments fall.

Note 10 indicates the foreign currencies, if applicable, to which the Fund had significant exposure, including both monetary and non-monetary financial instruments, and illustrates the potential impact, in Canadian dollar terms, to the Fund's net assets had the Canadian dollar strengthened or weakened by 5% relative to all foreign currencies, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to currency risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts including forward currency contracts. Other financial assets and liabilities (including dividends and interest receivable, and receivables/payables for investments sold/purchased) that are denominated in foreign currencies do not expose the Fund to significant currency risk.

iv. Interest rate risk

Interest rate risk arises on interest-bearing financial instruments. The Fund is exposed to the risk that the value of interest-bearing financial instruments will fluctuate due to changes in the prevailing levels of market interest rates. Generally, these securities increase in value when interest rates fall and decrease in value when interest rates rise.

If significant, Note 10 summarizes the Fund's interest-bearing financial instruments by remaining term to maturity and illustrates the potential impact to the Fund's net assets had prevailing interest rates increased or decreased by 1%, assuming a parallel shift in the yield curve, all other variables held constant. The Fund's sensitivity to interest rate changes was estimated using weighted average duration. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to interest rate risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts. Cash and cash equivalents and other money market instruments are short term in nature and are not generally subject to significant amounts of interest rate risk.

v. Other price risk

Other price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment. All investments present a risk of loss of capital. This risk is managed through a careful selection of investments and other financial instruments within the parameters of the investment strategies. Except for certain derivative contracts, the maximum risk resulting from financial instruments is equivalent to their fair value. The maximum risk of loss on certain derivative contracts such as forwards, swaps, and futures contracts is equal to their notional values. In the case of written call (put) options and short futures contracts, the loss to the Fund continues to increase, theoretically without limit, as the fair value of the underlying interest increases (decreases). However, these instruments are generally used within the overall investment management process to manage the risk from the underlying investments and do not typically increase the overall risk of loss to the Fund. This risk is mitigated by ensuring that the Fund holds a combination of the underlying interest, cash cover and/or margin that is equal to or greater than the value of the derivative contract.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

Financial Instruments Risk (cont'd)

v. Other price risk (cont'd)

Other price risk typically arises from exposure to equity and commodity securities. If significant, Note 10 illustrates the potential increase or decrease in the Fund's net assets, had the prices on the respective exchanges for these securities increased or decreased by 10%, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to other price risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts.

vi. Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund. Note 10 summarizes the Fund's exposure, if applicable and significant, to credit risk.

If presented, credit ratings and rating categories are based on ratings issued by a designated rating organization. Indirect exposure to credit risk may arise from fixedincome securities, such as bonds, held by underlying funds and ETFs, if any. The fair value of debt securities includes consideration of the creditworthiness of the debt issuer.

To minimize the possibility of settlement default, securities are exchanged for payment simultaneously, where market practices permit, through the facilities of a central depository and/or clearing agency where customary.

The carrying amount of investments and other assets represents the maximum credit risk exposure as at the date of the Statement of Financial Position. The Fund may enter into securities lending transactions with counterparties and it may also be exposed to credit risk from the counterparties to the derivative instruments it may use. Credit risk associated with these transactions is considered minimal as all counterparties have a rating equivalent to a designated rating organization's credit rating of not less than A-1 (low) on their short-term debt and of A on their long-term debt, as applicable.

vii. Underlying funds

The Fund may invest in underlying funds and may be indirectly exposed to currency risk, interest rate risk, other price risk and credit risk from fluctuations in the value of financial instruments held by the underlying funds. Note 10 summarizes the Fund's exposure, if applicable and significant, to these risks from underlying funds.

Other Information

Abbreviations

Foreign currencies, if any, are presented in these financial statements using the following abbreviated currency codes:

Currency Code	Description	Currency Code	Description	Currency Code	Description
AUD	Australian dollars	HUF	Hungarian forint	PLN	Polish zloty
AED	United Arab Emirates Dirham	IDR	Indonesian rupiah	QAR	Qatar Rial
BRL	Brazilian real	ILS	Israeli shekel	RON	Romanian leu
CAD	Canadian dollars	INR	Indian rupee	RUB	Russian ruble
CHF	Swiss franc	JPY	Japanese yen	SAR	Saudi riyal
CZK	Czech koruna	KOR	South Korean won	SEK	Swedish krona
CLP	Chilean peso	MXN	Mexican peso	SGD	Singapore dollars
CNY	Chinese yuan	MYR	Malaysian ringgit	THB	Thailand baht
СОР	Colombian peso	NGN	Nigerian naira	TRL	Turkish lira
DKK	Danish krone	NOK	Norwegian krona	USD	United States dollars
EGP	Egyptian pound	NTD	New Taiwan dollar	VND	Vietnamese dong
EUR	Euro	NZD	New Zealand dollars	ZAR	South African rand
GBP	United Kingdom pounds	PEN	Peruvian nuevo sol	ZMW	Zambian kwacha
GHS	Ghana Cedi	PHP	Philippine peso		
HKD	Hong Kong dollars	PKR	Pakistani rupee		

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a))

(a) Fund Formation and Series Information

Date of Formation: June 21, 2007

The Fund may issue an unlimited number of securities of each series. The number of issued and outstanding securities of each series is disclosed in the Statements of Changes in Financial Position.

Series Offered by Mackenzie Financial Corporation (180 Queen Street West, Toronto, Ontario, M5V 3K1; 1-800-387-0614; www.mackenzieinvestments.com)

Series A, Series T5 and Series T8 securities are offered to retail investors investing a minimum of \$500 (\$5,000 for Series T5 and Series T8). Investors in Series T5 and Series T8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series AR securities are offered to retail investors in a Registered Disability Savings Plan offered by Mackenzie.

Series D securities are offered to retail investors investing a minimum of \$500 through a discount brokerage or other account approved by Mackenzie. Investors in Series D securities also want to receive a monthly cash flow of 5% per year.

Series F and Series F8 securities are offered to investors who are enrolled in a dealer-sponsored fee-for-service or wrap program, who are subject to an asset-based fee rather than commissions on each transaction and who invest at least \$500 (\$5,000 for Series F8); they are also available to employees of Mackenzie and its subsidiaries, and directors of Mackenzie. Investors in Series F and Series F8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series FB and Series FB5 securities are offered to retail investors investing a minimum of \$500. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series FB5 securities also want to receive a monthly cash flow of 5% per year.

Series I securities are offered to retail investors investing a minimum of \$500 in a qualified group plan with a minimum of \$10,000,000 in assets. Investors in Series I securities also want to receive a monthly cash flow of 5% per year.

Series IG securities are offered exclusively to mutual funds managed by I.G. Investment Management, Ltd.

Series 0 and Series 05 securities are offered only to investors investing a minimum of \$500,000 who are enrolled in Mackenzie Portfolio Architecture Service or Open Architecture Service; certain institutional investors; investors in a qualified group plan, and certain qualifying employees of Mackenzie and its subsidiaries. Investors in Series 0 and Series 05 securities also want to receive a monthly cash flow of 5% per year.

Series PW, Series PWT5 and Series PWT8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors in Series PWT5 and Series PWT8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series PWFB and Series PWFB5 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWFB5 securities also want to receive a monthly cash flow of 5% per year.

Series PWR securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000 in a Registered Disability Savings Plan offered by Mackenzie.

Series PWX and Series PWX8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWX and Series PWX8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series R securities are offered only to other funds managed by Mackenzie on a non-prospectus basis in connection with fund-of-fund arrangements.

Series S securities are offered to The Canada Life Assurance Company and certain other mutual funds, but may be sold to other investors as determined by Mackenzie.

Series UM securities are offered only to certain institutional investors.

Series CL, Series J, Series PWT6, Series T6, Series U and Series U5 securities are no longer available for sale.

Series Distributed by LBC Financial Services Inc. (1360 René-Lévesque Blvd. West, 13th Floor, Montréal, Québec H3G 0A9; 1-800-522-1846; www.laurentianbank.ca/mackenzie)

Series LB securities are offered to retail investors investing a minimum of \$500.

Series LF securities are offered to retail investors investing a minimum of \$500, who are enrolled in the LBC Private Banking sponsored fee-for-service program.

Series LW securities are offered through our Preferred Pricing Program to certain high net worth investors who invest a minimum of \$100,000.

Effective June 1, 2022, an investor may purchase the Fund under a sales charge purchase option and a no-load purchase option. Not all purchase options are available under each series of the Fund. The sales charge under the sales charge purchase option is negotiated by the investor with their dealer. Securities purchased before June 1, 2022, under the redemption charge purchase option, low-load 3 purchase option and low-load 2 purchase option (collectively the "deferred sales charge purchase options") may continue to be held in investor accounts. Investors may switch from securities of a Mackenzie fund previously purchased under these deferred sales charge purchase options to securities of other Mackenzie funds, under the same purchase option, until such time as the redemption schedule has expired. For further details, please refer to the Fund's Simplified Prospectus and Fund Facts.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (a) Fund Formation and Series Information (cont'd)

	inception/		
Series	Reinstatement Date	Management Fee	Administration Fee
Series A	March 28, 2008	2.00%	0.28%
Series AR	October 15, 2013	2.00%	0.31%
Series CL	None issued (4)	n/a	n/a
Series D	March 19, 2014	1.00%(3)	0.20%
Series F	July 11, 2007	0.80%	0.15%
Series F8	May 21, 2008	0.80%	0.15%
Series FB	October 26, 2015	1.00%	0.28%
Series FB5	October 26, 2015	1.00%	0.28%
Series I	March 12, 2008	1.35%	0.28%
Series IG	October 30, 2023	n/a	n/a
Series J	November 25, 2010	1.75%	0.25%
Series O	July 9, 2007	_(1)	n/a
Series 05	March 27, 2013	_(1)	n/a
Series PW	October 29, 2013	1.80%	0.15%
Series PWFB	April 3, 2017	0.80%	0.15%
Series PWFB5	April 3, 2017	0.80%	0.15%
Series PWR	April 1, 2019	1.80%	0.15%
Series PWT5	April 3, 2017	1.80%	0.15%
Series PWT6	April 3, 2017	1.80%	0.15%
Series PWT8	December 9, 2013	1.80%	0.15%
Series PWX	November 29, 2013	_(2)	_ (2)
Series PWX8	May 8, 2014	_(2)	_ (2)
Series R	July 9, 2014	n/a	n/a
Series S	July 15, 2011	_(1)	0.03%
Series T5	July 9, 2007	2.00%	0.28%
Series T6	September 4, 2007	2.00%	0.28%
Series T8	July 16, 2007	2.00%	0.28%

Inception/

May 14, 2009

May 27, 2009

October 16, 2017

December 2, 2014

December 7, 2018

December 1, 2017

Series U

Series U5

Series UM

Series LB

Series LF

Series LW

Expiration Date of Non-Capital Losses

1.70%

1.70%

0.75%

2.00%

0.80%

1.80%

0.28%

0.28%

0.15%

0.28%

0.15%

0.15%

Total Capital	Total Non-Capital	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	
Loss \$	Loss \$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	
12,216	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_

⁽¹⁾ This fee is negotiable and payable directly to Mackenzie by investors in this series.

⁽²⁾ This fee is payable directly to Mackenzie by investors in this series through redemptions of their securities.

⁽³⁾ Prior to April 4, 2022, the management fee for Series D was charged to the Fund at a rate of 1.25%.

⁽⁴⁾ The series' original start date was January 11, 2021. All securities in the series were redeemed on January 9, 2024.

⁽b) Tax Loss Carryforwards

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a)) (cont'd)

(c) Securities Lending

	March 31, 2024	March 31, 2023
	(\$)	(\$)
Value of securities loaned	91,623	98,252
Value of collateral received	96,596	103,388

	March 3	31, 2024	March 3	1, 2023
	(\$)	(%)	(\$)	(%)
Gross securities lending income	452	100.0	326	100.0
Tax withheld	(54)	(11.9)	-	_
	398	88.1	326	100.0
Payments to securities lending agent	(71)	(15.7)	(59)	(18.1)
Securities lending income	327	72.4	267	81.9

(d) Commissions

	(\$)
March 31, 2024	633
March 31, 2023	446

(e) Risks Associated with Financial Instruments

i. Risk exposure and management

The Fund seeks long-term capital growth and current income by investing primarily in equities of companies anywhere in the world that are expected to pay dividends. It may also invest in other types of securities that are expected to distribute income. The Fund will not invest more than 25% of its assets in emerging markets.

ii. Currency risk

The tables below summarize the Fund's exposure to currency risk.

			Marc	h 31, 2024				
				_		Impact on	net assets	
Curronov	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure*	Strengthen	ed by 5% %	Weakened	by 5% %
Currency				(\$)	(φ)	/0	(Φ)	/0
USD	3,676,541	67	_	3,676,608				
EUR	845,016	_	(205,672)	639,344				
GBP	402,920	_	(56,758)	346,162				
JPY	248,849	_	_	248,849				
CHF	142,256	_	(2)	142,254				
DKK	108,051	_	_	108,051				
NTD	98,907	_	_	98,907				
SGD	69,234	_	_	69,234				
INR	48,735	_	_	48,735				
SEK	44,843	_	_	44,843				
HKD	24,199	_	_	24,199				
CNY	14,809	4,403	_	19,212				
Total	5,724,360	4,470	(262,432)	5,466,398				
% of Net Assets	96.5	0.1	(4.4)	92.2				
Total currency rate sens	sitivity				(273,320)	(4.6)	273,320	4.6

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (e) Risks Associated with Financial Instruments (cont'd)

ii. Currency risk (cont'd)

March 31, 2023

				1101, 2020				
				_		Impact on	net assets	
Currency	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengthene	d by 5% %	Weakened (\$)	by 5% %
USD	2,881,494	2,197	_	2,883,691			<u> </u>	
EUR	731,667	6,774	(145,808)	592,633				
GBP	310,550	_	(30,812)	279,738				
JPY	181,083	_	_	181,083				
CHF	182,380	_	(27,817)	154,563				
HKD	82,778	_	_	82,778				
DKK	75,406	_	_	75,406				
SGD	61,434	_	_	61,434				
NTD	60,483	244	_	60,727				
INR	29,479	_	_	29,479				
SEK	25,010	_	_	25,010				
CNY	21,552	234	_	21,786				
Total	4,643,316	9,449	(204,437)	4,448,328				
% of Net Assets	96.7	0.2	(4.3)	92.6				
Total currency rate sens	sitivity				(222,416)	(4.6)	222,416	4.6

^{*} Includes both monetary and non-monetary financial instruments

As at March 31, 2024 and 2023, the Fund did not have a significant exposure to interest rate risk.

iv. Other price risk

The table below summarizes the Fund's exposure to other price risk.

	Increased by	10%	Decreased b	y 10%
Impact on net assets	(\$)	(%)	(\$)	(%)
March 31, 2024	575,054	9.7	(575,054)	(9.7)
March 31, 2023	468,551	9.8	(468,551)	(9.8)

v. Credit risk

As at March 31, 2024 and 2023, the Fund did not have a significant exposure to credit risk.

(f) Fair Value Classification

The table below summarizes the fair value of the Fund's financial instruments using the fair value hierarchy described in note 3.

	March 31, 2024			March 31, 2023				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)
Equities	5,724,360	_	_	5,724,360	2,881,494	1,761,822	_	4,643,316
Mutual Funds	26,181	_	_	26,181	42,198	_	_	42,198
Derivative assets	_	2,423	_	2,423	_	96	_	96
Derivative liabilities	_	(944)	_	(944)	_	(3,559)	_	(3,559)
Short-term investments	_	180,247	_	180,247	_	125,254	_	125,254
Total	5,750,541	181,726	_	5,932,267	2,923,692	1,883,613	_	4,807,305

The Fund's policy is to recognize transfers into and transfers out of fair value hierarchy levels as of the date of the event or change in circumstances that caused the transfer

During the period ended March 31, 2024, non-North American equities frequently transferred between Level 1 (unadjusted quoted market prices) and Level 2 (adjusted market prices). As at March 31, 2024, these securities were classified as Level 1 (2023 – Level 2).

iii. Interest rate risk

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (g) Investments by the Manager and Affiliates

The investments held by the Manager, other funds managed by the Manager, and funds managed by affiliates of the Manager, investing in series CL, IG or S of the Fund, as applicable (as described in *Fund Formation and Series Information* in note 10), were as follows:

	March 31, 2024	March 31, 2023
	(\$)	(\$)
The Manager	6,478	4,607
Other funds managed by the Manager	207,951	230,169
Funds managed by affiliates of the Manager	22,641	29,062

(h) Offsetting of Financial Assets and Liabilities

The tables below present financial assets and financial liabilities that are subject to master netting arrangements or other similar agreements and the net impact on the Fund's Statements of Financial Position if all set-off rights were exercised as part of future events such as bankruptcy or termination of contracts. No amounts were offset in the financial statements.

		March 31, 2024				
	Gross amount of assets/liabilities (\$)	Amount available for offset (\$)	Margin (\$)	Net amount (\$)		
Unrealized gains on derivative contracts	2,423	(835)	-	1,588		
Unrealized losses on derivative contracts	(835)	835	-	-		
Liability for options written	-	_	_	_		
Total	1,588	_	_	1,588		

	March 31, 2023				
	Gross amount of assets/liabilities (\$)	Amount available for offset (\$)	Margin (\$)	Net amount (\$)	
Unrealized gains on derivative contracts	40	(40)	_	_	
Unrealized losses on derivative contracts	(1,088)	40	_	(1,048)	
Liability for options written	_	_	_	_	
Total	(1,048)	-	-	(1,048)	

(i) Interest in Unconsolidated Structured Entities

The Fund's investment details in the Underlying Funds as at March 31, 2024 and 2023 are as follows:

March 31, 2024	% of Underlying Fund's Net Assets	Fair Value of Fund's Investment (\$)	
Mackenzie International Dividend Fund Series R	5.1	26,181	
March 31, 2023	% of Underlying Fund's Net Assets	Fair Value of Fund's Investment (\$)	
Mackenzie Global China Fund Series R	71.3	20,925	
Mackenzie International Dividend Fund Series R	3.8	21,273	